<SEC-DOCUMENT>0001628280-22-012619.txt : 20220506
<SEC-HEADER>0001628280-22-012619.hdr.sgml : 20220506
<ACCEPTANCE-DATETIME>20220505160323
ACCESSION NUMBER:		0001628280-22-012619
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20220505
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220505
DATE AS OF CHANGE:		20220505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARDELYX, INC.
		CENTRAL INDEX KEY:			0001437402
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36485
		FILM NUMBER:		22896091

	BUSINESS ADDRESS:	
		STREET 1:		34175 ARDENWOOD BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94555
		BUSINESS PHONE:		510-745-7047

	MAIL ADDRESS:	
		STREET 1:		34175 ARDENWOOD BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94555

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTERYX INC
		DATE OF NAME CHANGE:	20080611
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ardx-20220505.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:4cc903a2-1341-48b0-a208-d4b59e927ea5,g:1a71149b-3377-4636-9d62-47ebad1efd93,d:854eadf3938f4eb6b0f9db36addb0087--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ardx-20220505</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N180L2ZyYWc6ODMxMzU2MTRhOWM2NGUzZThiM2MzYjZiYmM1ZjI4ZGQvdGFibGU6YmY1ZWY1ZjAxNzE5NDRhY2IwOTRkNTM1NWU4NjA5YWUvdGFibGVyYW5nZTpiZjVlZjVmMDE3MTk0NGFjYjA5NGQ1MzU1ZTg2MDlhZV8yLTEtMS0xLTIyODA3_8c42eca7-2040-4148-a522-06df06dc2d29">0001437402</ix:nonNumeric><ix:nonNumeric contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N180L2ZyYWc6ODMxMzU2MTRhOWM2NGUzZThiM2MzYjZiYmM1ZjI4ZGQvdGFibGU6YmY1ZWY1ZjAxNzE5NDRhY2IwOTRkNTM1NWU4NjA5YWUvdGFibGVyYW5nZTpiZjVlZjVmMDE3MTk0NGFjYjA5NGQ1MzU1ZTg2MDlhZV8zLTEtMS0xLTIyODA3_ee43dacf-5a61-4c1e-9747-923da4f0e1aa">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ardx-20220505.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i854eadf3938f4eb6b0f9db36addb0087_1"></div><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGV4dHJlZ2lvbjo0MjkwOGMzYTVkMmM0NzE0YTE4NjA1M2RlZTIxMTY2MF8xMjYw_280c70ff-9661-45fc-875d-06a6547002e3">8-K</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported):&#160;<ix:nonNumeric contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGV4dHJlZ2lvbjo0MjkwOGMzYTVkMmM0NzE0YTE4NjA1M2RlZTIxMTY2MF8yMzE_951af91f-5fa7-4d92-a908-ea563436372e">May 5, 2022</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><img src="ardx-20220505_g1.jpg" alt="ardx-20220505_g1.jpg" style="height:75px;margin-bottom:5pt;vertical-align:text-bottom;width:75px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGV4dHJlZ2lvbjo0MjkwOGMzYTVkMmM0NzE0YTE4NjA1M2RlZTIxMTY2MF8xMjYx_559f793c-c3ab-4422-82f7-1bed5a7c8158">ARDELYX, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGFibGU6YzVjOTI4ZDBmMWM4NGMwZWI0OTA2YzA2ZjYxYmQyMmIvdGFibGVyYW5nZTpjNWM5MjhkMGYxYzg0YzBlYjQ5MDZjMDZmNjFiZDIyYl8wLTAtMS0xLTIyODA3_cd7b2dbd-7697-4c32-8dbf-26e9bf3b5059">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGFibGU6YzVjOTI4ZDBmMWM4NGMwZWI0OTA2YzA2ZjYxYmQyMmIvdGFibGVyYW5nZTpjNWM5MjhkMGYxYzg0YzBlYjQ5MDZjMDZmNjFiZDIyYl8wLTEtMS0xLTIyODA3_87f7d3e0-6cbd-496a-a160-4e345e28d77c">001-36485</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGFibGU6YzVjOTI4ZDBmMWM4NGMwZWI0OTA2YzA2ZjYxYmQyMmIvdGFibGVyYW5nZTpjNWM5MjhkMGYxYzg0YzBlYjQ5MDZjMDZmNjFiZDIyYl8wLTItMS0xLTIyODA3_f929f8b6-447d-4ee0-bcd6-657084ec6304">26-1303944</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction<br/>of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer<br/>Identification Number)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGV4dHJlZ2lvbjo0MjkwOGMzYTVkMmM0NzE0YTE4NjA1M2RlZTIxMTY2MF8xMjU0_b465c7d9-37fc-45be-bf0c-9523ba50a5b8">400 FIFTH AVE.</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGV4dHJlZ2lvbjo0MjkwOGMzYTVkMmM0NzE0YTE4NjA1M2RlZTIxMTY2MF8xMjU1_3f97c815-d244-441e-b3a7-0dd8c334317a">SUITE 210</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGV4dHJlZ2lvbjo0MjkwOGMzYTVkMmM0NzE0YTE4NjA1M2RlZTIxMTY2MF8xMjYy_d8eb9ee7-255e-4375-9f2b-80e1ffffedd7">WALTHAM</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGV4dHJlZ2lvbjo0MjkwOGMzYTVkMmM0NzE0YTE4NjA1M2RlZTIxMTY2MF8xMjYz_07327b37-e616-40f2-ae48-4484672abe5e">MA</ix:nonNumeric>SSACHUSETTS&#160;<ix:nonNumeric contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGV4dHJlZ2lvbjo0MjkwOGMzYTVkMmM0NzE0YTE4NjA1M2RlZTIxMTY2MF8xMjU2_a71ea345-d527-4d52-b848-179353814431">02451</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices, including Zip Code)</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGV4dHJlZ2lvbjo0MjkwOGMzYTVkMmM0NzE0YTE4NjA1M2RlZTIxMTY2MF8xMjY1_de5bf237-d03b-4e6f-8b1d-8d29d6d475ff">510</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGV4dHJlZ2lvbjo0MjkwOGMzYTVkMmM0NzE0YTE4NjA1M2RlZTIxMTY2MF8xMjU3_bcf75b2b-2986-4df4-b256-400ecc79fe52">745-1700</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:2.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGFibGU6YzRmMzRkOWEzMjk3NDM4YmE2Mzk3ZGM4YjNlZDg4YjcvdGFibGVyYW5nZTpjNGYzNGQ5YTMyOTc0MzhiYTYzOTdkYzhiM2VkODhiN18wLTAtMS0xLTIyODA3_ed52a09d-d95e-432d-940b-41f693440027">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGFibGU6YzRmMzRkOWEzMjk3NDM4YmE2Mzk3ZGM4YjNlZDg4YjcvdGFibGVyYW5nZTpjNGYzNGQ5YTMyOTc0MzhiYTYzOTdkYzhiM2VkODhiN18xLTAtMS0xLTIyODA3_958580c8-68f0-4da9-b315-a03f300eb14f">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGFibGU6YzRmMzRkOWEzMjk3NDM4YmE2Mzk3ZGM4YjNlZDg4YjcvdGFibGVyYW5nZTpjNGYzNGQ5YTMyOTc0MzhiYTYzOTdkYzhiM2VkODhiN18yLTAtMS0xLTIyODA3_d6dfccba-46ce-4627-a18e-f62707441bb2">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGFibGU6YzRmMzRkOWEzMjk3NDM4YmE2Mzk3ZGM4YjNlZDg4YjcvdGFibGVyYW5nZTpjNGYzNGQ5YTMyOTc0MzhiYTYzOTdkYzhiM2VkODhiN18zLTAtMS0xLTIyODA3_aec8fadb-14e7-4526-8c29-508d1a407325">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGFibGU6ZDM0NTY1YTNkOTA3NGI0MWFiYTBjOGE3YWJmNWU2YWMvdGFibGVyYW5nZTpkMzQ1NjVhM2Q5MDc0YjQxYWJhMGM4YTdhYmY1ZTZhY18xLTAtMS0xLTIyODA3_a6e967f6-befb-4e43-ace9-51671bfdb04a">Common Stock, par value $0.0001</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGFibGU6ZDM0NTY1YTNkOTA3NGI0MWFiYTBjOGE3YWJmNWU2YWMvdGFibGVyYW5nZTpkMzQ1NjVhM2Q5MDc0YjQxYWJhMGM4YTdhYmY1ZTZhY18xLTItMS0xLTIyODA3_202fd247-181e-4b91-b729-5a83fa02fc2b">ARDX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGFibGU6ZDM0NTY1YTNkOTA3NGI0MWFiYTBjOGE3YWJmNWU2YWMvdGFibGVyYW5nZTpkMzQ1NjVhM2Q5MDc0YjQxYWJhMGM4YTdhYmY1ZTZhY18xLTQtMS0xLTIyODA3_1f0db5c8-5479-476e-8862-3faa68d1bb71">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGV4dHJlZ2lvbjo0MjkwOGMzYTVkMmM0NzE0YTE4NjA1M2RlZTIxMTY2MF8xMjU4_5e247c73-a828-44b3-b8d1-c45eb5c1a59b">&#9744;</ix:nonNumeric></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i854eadf3938f4eb6b0f9db36addb0087_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-top:12pt;padding-left:58.5pt;text-indent:-58.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.02&#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;5, 2022, Ardelyx, Inc. (the &#8220;Company&#8221;) announced its financial results for the fiscal quarter ended March&#160;31, 2022. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information furnished under this Item 2.02 shall not be considered &#8220;filed&#8221; under the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or under&#160;the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered &#8220;filed&#8221; or incorporated by reference therein.</span></div><div id="i854eadf3938f4eb6b0f9db36addb0087_10"></div><div style="-sec-extract:summary;margin-top:12pt;padding-left:58.5pt;text-indent:-58.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d) Exhibits.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:7.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.711%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.166%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ardx-20220331xexhibit991.htm">Press release of Ardelyx, Inc.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i854eadf3938f4eb6b0f9db36addb0087_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:41.924%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.158%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.618%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 5, 2022</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARDELYX, INC.</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Robert Felsch</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert Felsch</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Accounting Officer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ardx-20220331xexhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i2d42c47ba1754b9689b6343f956442f4_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt;text-align:right"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:39px;margin-bottom:5pt;vertical-align:text-bottom;width:125px"></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit&#160;99.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:112%">Ardelyx Reports First Quarter 2022 Financial </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Results and Recent Business Highlights</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:107%"> Conference Call Scheduled for 4&#58;30 PM Eastern Time Today</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">WALTHAM, Mass., May&#160;5, 2022 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">- Ardelyx, Inc. (Nasdaq&#58; ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today provided a business update and reported financial results for the first quarter ended March&#160;31, 2022. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8220;Ardelyx is off to a great start in 2022, with the commercial launch of  IBSRELA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:174%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">, our first-in-class, novel therapy for the treatment of IBS-C in adults,&#8221; said Mike Raab, president and chief executive officer of Ardelyx. &#8220;Initial channel stocking began in late March, the sales force is mobilized across the country, and early response to the product as a new treatment option has been positive. In parallel, we continue to persist in our pursuit of FDA approval for XPHOZAH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:174%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">, our first-in-class, phosphate absorption inhibitor, and received notification from the FDA that an advisory committee meeting will be convened to get further input from experts, augmented with clinicians familiar with the clinical management of hyperphosphatemia.&#8221; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">Recent Business Highlights</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;padding-left:13.8pt">On April 4, 2022, the company announced the launch of IBSRELA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:174%;position:relative;top:-4.2pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(tenapanor), the first and only NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. IBSRELA is the first FDA-approved product for Ardelyx. Commercial efforts are focused on the 9,000 HCPs who account for 50% of the prescriptions of IBS-C indicated products, with broad-based distribution, a targeted specialty sales force, and omnichannel tactics. Marketing messages center on the multifactorial pathophysiology of IBS-C, and the role novel mechanism IBSRELA can play to address important medical unmet needs. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;padding-left:13.8pt">The company presented multiple presentations at the National Kidney Foundation 2022 Spring Clinical Meetings, in Boston, MA on</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">April 6-10, 2022, covering additional positive clinical observations of XPHOZAH an investigational, first-in-class, phosphate absorption inhibitor for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt;text-align:right"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:39px;margin-bottom:5pt;vertical-align:text-bottom;width:125px"></div></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;padding-left:13.8pt">On April 11, 2022, the company announced it reached an agreement with its Japanese collaboration partner, Kyowa Kirin Co. Ltd., to amend the license agreement, originally executed in 2017. Under the amendment, in consideration for a reduction in the royalty rate due Ardelyx upon net sales in Japan, Kyowa Kirin has agreed to pay Ardelyx consideration of up to an additional U.S. $40 million payable in two tranches. The first payment is due following Kyowa Kirin's filing with the Japanese Ministry of Health, Labour and Welfare (MHLW) of its application for marketing approval for tenapanor and the second payment is due following MHLW&#8217;s approval to market tenapanor for hyperphosphatemia in Japan. Kyowa Kirin is finalizing its Phase 3 clinical program for tenapanor for hyperphosphatemia and has disclosed its current expectation to file for approval with MHLW in the second half of 2022 and its current expectation that it will receive a decision from MHLW regarding its application in the second half of 2023. The royalty rate will be reduced from the high teens to low double digits for a two-year period of time following the first commercial sale in Japan, and then to mid-single digits for the remainder of the royalty term.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;padding-left:13.8pt">On April 25, 2022, the company announced that the Office of New Drugs (OND), Center for Drug Evaluation and Research (CDER) of the U.S. Food and Drug Administration (FDA), has provided an interim response to Ardelyx&#8217;s second level of appeal of the Complete Response Letter (CRL) received on July 28, 2021, for XPHOZAH. The OND noted that additional input from the Cardiovascular and Renal Drug Advisory Committee augmented with expert clinicians would be valuable in further considering the clinical meaningfulness of the phosphate lowering effect demonstrated in Ardelyx&#8217;s Phase 3 clinical program for XPHOZAH. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">First Quarter 2022 Financial Results</font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">Cash Position&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%"> As of March&#160;31, 2022, we had total cash, cash equivalents and investments of $89.7&#160;million, as compared to total cash, cash equivalents and investments of $116.7&#160;million as of December&#160;31, 2021.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">Product Sales&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%"> We recognized our first commercial product sales, net for IBSRELA during March 2022 in the amount of $0.5&#160;million.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%;padding-left:13.8pt">Collaboration Revenue&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%"> We generated $18&#160;thousand in collaboration revenue for the quarter ended March&#160;31, 2022, as compared to $6.6&#160;million for the quarter ended March&#160;31, 2021. The decrease in our collaboration revenue was primarily the result of a $5.0 million development milestone which we earned in 2021, as well as recognition of the previously received upfront payment from the KKC 2019 research and collaboration agreement that was fully earned and recognized as revenue as of December 31, 2021. </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt;text-align:right"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:39px;margin-bottom:5pt;vertical-align:text-bottom;width:125px"></div></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">R&#38;D Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#58; Research and development expenses were $8.9&#160;million for the quarter ended March&#160;31, 2022, a decrease of $11.6&#160;million, or 56.7%, compared to $20.5&#160;million for the quarter ended March&#160;31, 2021. Research and development expenses included non-cash stock compensation expense of approximately $1.2 million and $1.1 million in the quarters ended March 31, 2022, and 2021, respectively. The decrease in our R&#38;D expenses is primarily the result of lower clinical study costs from the OPTIMIZE study, lower tenapanor manufacturing expenses as we have begun to capitalize costs associated with the production of IBSRELA to inventory, and lower expenses for research following the elimination of our research function in the fourth quarter of 2021. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">SG&#38;A Expenses&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%"> Selling, general and administrative expenses were $19.3&#160;million for the quarter ended March&#160;31, 2022, an increase of $2.2&#160;million, or 12.9%, compared to $17.1&#160;million for the quarter ended March&#160;31, 2021. Selling, general and administrative expenses included non-cash stock compensation expense of approximately $2.5 million and $2.0 million in the quarters ended March 31, 2022, and 2021, respectively. The increase in selling, general and administrative expenses was primarily due to an increase in costs associated with preparations for the commercial launch of IBSRELA. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">Net Loss&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Net loss for the quarter ended March&#160;31, 2022 was $28.1&#160;million, or $0.21 per share, compared to $33.2&#160;million, or $0.34 per share, for the quarter ended March&#160;31, 2021.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:150%">Conference Call Details</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">The company will host a conference call today, May&#160;5, 2022, at 4&#58;30 PM ET to review its financial results and provide a business overview. To participate in the conference call, please dial (866) 777-2509 (domestic) or (412) 317-5413 (international) and ask to be joined into the Ardelyx, Inc. call. A webcast of the call can also be accessed by visiting the Investor page of the company's website at www.ardelyx.com and will be available on the website for 30 days following the call.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">IMPORTANT SAFETY INFORMATION</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WARNING&#58; RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS</font></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">IBSRELA is contraindicated in patients less than 6 years of age&#59; in nonclinical studies in young juvenile rats administration of tenapanor caused deaths presumed to be due to dehydration. Avoid use of IBSRELA in patients 6 years to less than 12 years of age. The safety and effectiveness of IBSRELA have not been established in patients less than 18 years of age.</font></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt;text-align:right"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:39px;margin-bottom:5pt;vertical-align:text-bottom;width:125px"></div></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">CONTRAINDICATIONS</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;padding-left:13.8pt">IBSRELA is contraindicated in patients less than 6 years of age due to the risk of serious dehydration. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;padding-left:13.8pt">IBSRELA is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">WARNINGS AND PRECAUTIONS</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">Risk of Serious Dehydration in Pediatric Patients</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;padding-left:13.8pt">IBSRELA is contraindicated in patients below 6 years of age. The safety and effectiveness of IBSRELA in patients less than 18 years of age have not been established. In young juvenile rats (less than 1 week old&#59; approximate human age equivalent of less than 2 years of age), decreased body weight and deaths occurred, presumed to be due to dehydration, following oral administration of tenapanor. There are no data available in older juvenile rats (human age equivalent 2 years to less than 12 years). </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;padding-left:13.8pt">Avoid the use of IBSRELA in patients 6 years to less than 12 years of age. Although there are no data in older juvenile rats, given the deaths in younger rats and the lack of clinical safety and efficacy data in pediatric patients, avoid the use of IBSRELA in patients 6 years to less than 12 years of age.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">Diarrhea </font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Diarrhea was the most common adverse reaction in two randomized, double-blind, placebo-controlled trials of IBS-C. Severe diarrhea was reported in 2.5% of IBSRELA-treated patients.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">If severe diarrhea occurs, suspend dosing and rehydrate patient.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">MOST COMMON ADVERSE REACTIONS </font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">The most common adverse reactions in IBSRELA-treated patients (incidence &#8805;2% and greater than placebo) were&#58; diarrhea (16% vs 4% placebo), abdominal distension (3% vs &#60;1%), flatulence (3% vs 1%) and dizziness (2% vs &#60;1%).</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">INDICATION </font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">IBSRELA (tenapanor) is indicated for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">Please see full Prescribing Information, including Boxed Warning, for additional risk information.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:150%">About Ardelyx, Inc.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Ardelyx was founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs. Ardelyx&#8217;s first approved product, IBSRELA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:174%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%"> (tenapanor) is available in the United States. Ardelyx is developing XPHOZAH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:174%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%"> (tenapanor), a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt;text-align:right"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:39px;margin-bottom:5pt;vertical-align:text-bottom;width:125px"></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">completed three successful Phase 3 trials. Ardelyx has a Phase 2 potassium secretagogue program, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and&#47;or heart disease and an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Forward Looking Statements</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">To the extent that statements contained in this press release are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995, including Ardelyx&#8217;s current expectation regarding the FDA&#8217;s plan to convene an Advisory Committee meeting to consider the NDA for XPHOZAH, Ardelyx&#8217;s belief regarding the role that IBSRELA can play in addressing unmet medical needs in IBS-C, Ardelyx&#8217;s expectation regarding the timing of Kyowa Kirin&#8217;s filing for marketing approval for tenapanor for hyperphosphatemia in Japan and Ardelyx&#8217;s expectations regarding the potential timing for Kyowa Kirin&#8217;s marketing approval in Japan. Such forward-looking statements involve substantial risks and uncertainties that could cause Ardelyx's future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties associated with the drug development process and the regulatory approval process, including uncertainties in the drug development and regulatory processes in Japan, and risks and uncertainties associated with the commercialization of drugs in the United States. Ardelyx undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ardelyx's business in general, please refer to Ardelyx's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May&#160;5, 2022, and its future current and periodic reports to be filed with the Securities and Exchange Commission.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Investor and Media Contacts&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Kimia Keshtbod </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">kkeshtbod&#64;ardelyx.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sylvia Wheeler</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Wheelhouse Life Science Advisors</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">swheeler&#64;wheelhouselsa.com</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt;text-align:right"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:39px;margin-bottom:5pt;vertical-align:text-bottom;width:125px"></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Alex Santos</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Wheelhouse Life Science Advisors</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">asantos&#64;wheelhouselsa.com</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i2d42c47ba1754b9689b6343f956442f4_4"></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-top:10pt;text-align:right"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:39px;margin-bottom:5pt;vertical-align:text-bottom;width:125px"></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ardelyx,&#160;Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Balance Sheets</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,077</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,428</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,627</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,261</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,394</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,487</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,045</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,362</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,910</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,752</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other assets</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,868</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,608</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,408</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,913</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders' equity</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,030</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,277</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,304</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,422</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liability</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,592</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,492</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,139</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,264</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,563</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,727</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,778</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,366</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,812</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,748</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,190</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,617</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,408</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,913</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Derived from the audited financial statements included in the Company&#8217;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2021.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i2d42c47ba1754b9689b6343f956442f4_7"></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-top:10pt;text-align:right"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:39px;margin-bottom:5pt;vertical-align:text-bottom;width:125px"></div></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ardelyx,&#160;Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Operations</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except share and per share amounts)</font></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"></td><td style="width:67.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.602%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 2.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 4pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 4pt 0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product supply revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing revenue</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,002</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative development revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,454</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,582</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 2.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 4pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 4pt 0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,851</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,456</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,339</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,131</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,275&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,587&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,807)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,005)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(746)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,100)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before provision for income taxes</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,069)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,154)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Provision for income taxes</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,071)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 4pt 0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,155)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per common share, basic and diluted</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.21)</font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.34)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares used in computing net loss per share - basic and diluted</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,934,795&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,179,241&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ardx-20220505.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:4cc903a2-1341-48b0-a208-d4b59e927ea5,g:1a71149b-3377-4636-9d62-47ebad1efd93-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ardx="http://www.ardelyx.com/20220505" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.ardelyx.com/20220505">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ardx-20220505_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ardx-20220505_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.ardelyx.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ardx-20220505_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:4cc903a2-1341-48b0-a208-d4b59e927ea5,g:1a71149b-3377-4636-9d62-47ebad1efd93-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_PreCommencementTenderOffer_021deab4-9dbf-448f-80a4-418f9590e4c0_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_24fb9112-6a2b-48ab-b9c9-88ffefb74d37_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_7e3843b4-27b1-46d3-9fbc-3fc69b1538e1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_9947c5bf-9ff3-43c7-9f2a-f0cf3c8c1ae9_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_cdfeff2f-e342-4772-8dc6-45cc9c89bb2b_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_aab46213-70a3-4f25-af98-51559aad837f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_26d1518b-616a-467b-aa4b-918b66dab6bf_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_94d4f025-2a1a-4630-a8b5-a01e83f4bb25_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9d5f3912-2289-4d9e-96bd-1cf1066cf149_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_2ce6dc4b-f620-49ff-8b31-f5e7ab1ca2f6_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_508bdd62-5192-49ea-b09c-86534cdd35b0_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_676ed509-b3a8-4d3f-8739-c50431a6976f_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ba766d9a-7de1-4817-86c9-f1448c6a8437_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_e40f75ca-f685-4d64-b698-dbe1b7fd4a9a_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_38951d97-de94-420a-a1ac-7617ef2709d7_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_d7d7b152-441c-433e-aeed-6dfd68c5d922_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_40c27314-d531-4cda-bdf6-4381f4a59734_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_9e0c7e57-07e3-44c0-80ba-5bd030f45924_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ee2e54fe-96b3-43dc-b04d-24bfc3f2e88e_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_e7978637-7609-4dbf-a00f-7ccbadfc3a10_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_5447847a-f0cf-419b-a880-93a192b6ebaf_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_776d91e4-25f0-4806-9a21-52d6dafd60af_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_16967bb4-11f3-4262-bf61-34b7c60e1d83_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ardx-20220505_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:4cc903a2-1341-48b0-a208-d4b59e927ea5,g:1a71149b-3377-4636-9d62-47ebad1efd93-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ardelyx.com/role/Cover" xlink:type="simple" xlink:href="ardx-20220505.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_1931802a-c97d-4bfc-81c7-752f76bb383b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_e4217fbe-b34a-43a0-8d96-c8adde140423" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1931802a-c97d-4bfc-81c7-752f76bb383b" xlink:to="loc_dei_DocumentType_e4217fbe-b34a-43a0-8d96-c8adde140423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_187af1bf-cf3b-4e6d-991a-bac73b356325" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1931802a-c97d-4bfc-81c7-752f76bb383b" xlink:to="loc_dei_DocumentPeriodEndDate_187af1bf-cf3b-4e6d-991a-bac73b356325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_8ce570f0-c469-435e-9707-4d3aa447904d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1931802a-c97d-4bfc-81c7-752f76bb383b" xlink:to="loc_dei_EntityRegistrantName_8ce570f0-c469-435e-9707-4d3aa447904d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1a87d573-2dad-4d81-b420-88fd63148fc7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1931802a-c97d-4bfc-81c7-752f76bb383b" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1a87d573-2dad-4d81-b420-88fd63148fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_c019b733-a63d-406e-8931-b94497283a04" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1931802a-c97d-4bfc-81c7-752f76bb383b" xlink:to="loc_dei_EntityFileNumber_c019b733-a63d-406e-8931-b94497283a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_0f07c28f-ba89-4b33-b1b0-116209889c94" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1931802a-c97d-4bfc-81c7-752f76bb383b" xlink:to="loc_dei_EntityTaxIdentificationNumber_0f07c28f-ba89-4b33-b1b0-116209889c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_b388f4cc-e691-4d8b-83f0-6b0b2a1d58c9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1931802a-c97d-4bfc-81c7-752f76bb383b" xlink:to="loc_dei_EntityAddressAddressLine1_b388f4cc-e691-4d8b-83f0-6b0b2a1d58c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_959c1630-5207-4dd6-aebc-58f00dfca80c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1931802a-c97d-4bfc-81c7-752f76bb383b" xlink:to="loc_dei_EntityAddressAddressLine2_959c1630-5207-4dd6-aebc-58f00dfca80c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_25a49071-80d9-4857-8574-783ef520ea9f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1931802a-c97d-4bfc-81c7-752f76bb383b" xlink:to="loc_dei_EntityAddressCityOrTown_25a49071-80d9-4857-8574-783ef520ea9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_91e86a8a-85d5-4b60-b60a-b5aacd6e5f12" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1931802a-c97d-4bfc-81c7-752f76bb383b" xlink:to="loc_dei_EntityAddressStateOrProvince_91e86a8a-85d5-4b60-b60a-b5aacd6e5f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b8f4ae3f-e28e-4f9e-8e30-ec6de9527ef9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1931802a-c97d-4bfc-81c7-752f76bb383b" xlink:to="loc_dei_EntityAddressPostalZipCode_b8f4ae3f-e28e-4f9e-8e30-ec6de9527ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_603de92c-6eb7-4c20-a415-d23bdef56207" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1931802a-c97d-4bfc-81c7-752f76bb383b" xlink:to="loc_dei_CityAreaCode_603de92c-6eb7-4c20-a415-d23bdef56207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_6dd9d8f7-2ed3-4ced-b965-f6c2856d1048" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1931802a-c97d-4bfc-81c7-752f76bb383b" xlink:to="loc_dei_LocalPhoneNumber_6dd9d8f7-2ed3-4ced-b965-f6c2856d1048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_8c37b81b-c426-4a32-9f7d-37c830866846" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1931802a-c97d-4bfc-81c7-752f76bb383b" xlink:to="loc_dei_WrittenCommunications_8c37b81b-c426-4a32-9f7d-37c830866846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_0987db78-8dd1-4faa-b1a3-05fddcbf6459" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1931802a-c97d-4bfc-81c7-752f76bb383b" xlink:to="loc_dei_SolicitingMaterial_0987db78-8dd1-4faa-b1a3-05fddcbf6459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_eb4ad566-4c47-4b4c-990c-c900e65bf8f1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1931802a-c97d-4bfc-81c7-752f76bb383b" xlink:to="loc_dei_PreCommencementTenderOffer_eb4ad566-4c47-4b4c-990c-c900e65bf8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_2e91a948-287d-46eb-8f86-9e5d942dfe9b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1931802a-c97d-4bfc-81c7-752f76bb383b" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_2e91a948-287d-46eb-8f86-9e5d942dfe9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b12f0470-d5b2-48c4-b289-79624be2340f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1931802a-c97d-4bfc-81c7-752f76bb383b" xlink:to="loc_dei_Security12bTitle_b12f0470-d5b2-48c4-b289-79624be2340f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_16cde6c0-bfcb-4934-be81-4ff0e8a8b23c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1931802a-c97d-4bfc-81c7-752f76bb383b" xlink:to="loc_dei_TradingSymbol_16cde6c0-bfcb-4934-be81-4ff0e8a8b23c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_85cdc81a-f459-4534-afbc-d98ac6804b70" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1931802a-c97d-4bfc-81c7-752f76bb383b" xlink:to="loc_dei_SecurityExchangeName_85cdc81a-f459-4534-afbc-d98ac6804b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_142db83b-c442-44a6-afc7-69b4902ce191" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1931802a-c97d-4bfc-81c7-752f76bb383b" xlink:to="loc_dei_EntityEmergingGrowthCompany_142db83b-c442-44a6-afc7-69b4902ce191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_35221a3b-d1dc-4d2d-af14-b163eb149e3a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1931802a-c97d-4bfc-81c7-752f76bb383b" xlink:to="loc_dei_EntityCentralIndexKey_35221a3b-d1dc-4d2d-af14-b163eb149e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_da730a54-8b5e-48e6-aadb-4c2684a1c8f4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1931802a-c97d-4bfc-81c7-752f76bb383b" xlink:to="loc_dei_AmendmentFlag_da730a54-8b5e-48e6-aadb-4c2684a1c8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ardx-20220505_g1.jpg
<TEXT>
begin 644 ardx-20220505_g1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !K &L# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MK)U77[32U(9@\O9 ?YU%2I"G'FF[(NG3G4ERP5V:U0RW=O",R31K]6%>>7_B
MN_O"0C^4G8+P?SK%DN)9CF1RQ]2:\BKG,$[4XW/7I9--J]25CU5M8L%.#<I4
MD>I6<K;5N(\_[U>1;CZFE#L#D'FN=9U4OK%&[R6'23/95=7&58,/8YI:\HM-
M;O[-@8IVP/X2>/RKJ]*\8QSE8KU=C'C>.E=U#-:-1VE[K.*OE5:FKQ]Y'644
MV.1)4#QL&4]"#3J]3<\O8**** "BBLG7]5&EZ>S*?WK\(/ZU%2I&G!SELBZ=
M.52:A'=F=XD\2"R4VMJP,Q^\W]VN"EFDGD+R,68]R:2:5II6D<Y9CDFF5\AB
ML5/$3YI;=$?7X7"PP\.6._5A5K3].N-3NA;VZY8]3V JK7HO@_3A::4)G7]Y
M,<Y]NU5@L-]8J\KVZDXW$_5Z7,M^A4@\"6PC'G7#E^^!6;K'@^2RA:>T<RHO
M+*1R!7:7VJ6FG>7]IE";SA<]ZM I+'D89&'YBO>EE^%FG"*LU]YX,<PQ4&IR
M=T_N/&:.E;'B73AIVKNJ#$<GSK_6L>OF:M-TYN$MT?34JBJ04X[,W]!\13:=
M,(Y6+P$\@]J]%@GCN85EB8,C#((KQNNL\(ZT8)Q93']VY^4GL:]7+<<X25*H
M]'MY'E9E@5.+JTUJM_,[RBBBOHSYP*\V\5Z@;S57C#92+Y0/?O7H=W((K2:0
MG&$)_2O(KB0S3O(>K')KQ<YJM0C374]K)J2<Y5'T(J***^=/HBQ8VS7E]# H
MSO<9^F>:]<@B$$$<2C 10OY5PG@BQ\V_DNV'RQC"_4UVU_=+96,UPQX12:^C
MRFDJ=%U9=?R1\YFU5U*RI1Z?FSS[Q=??;-9:,'*0#:/KUKK?"=]]LT6-6;+Q
M?(?PKS>:0S3R2L<EV)-=%X+OOL^J-;LV$F7CZBN'!XM_7'-_:_I'=C,(OJ:@
MOL_TS=\::?\ :-,%RH^>$_IWKSVO8[F!;FVDA?[KJ5->1WENUI>S0,,%&(K3
M.*'+455=3/)Z_-3=-]""GQ2-%*KH<,#D&F45XY[!ZUH]X+[3(9@>2N#^%7JY
M3P1<%[*:(_PL,?2NKK[+"5?:T(S9\9BZ7LJTH(I:N<:5<?[M>2M]XUZ[J,9E
MTZ=1UV&O(W!#D'K7CYTO?@_(]G)7[DEYCH[>:8$Q1,X'7:*62VN(ES)"Z#U(
MKL? 9'DW:]]P_E6CXR0MH;D#H036$,O4L-[?FZ;'1/,''$^PY>NY+X9MXK'1
M859T#N-[?,.]4/&E^!8)9Q,&>9N=ISQ7">;)_P ]&_.K>EEGU>TW$L?-'6J_
MM'GI+#QC:]E<C^SN2J\1*5[:V(?L-WC_ (]I?RI+>5[2[CE&5:-P2/QKU\_Z
MG_@->2:GSJEU_P!=#6>-P2PJC*,KW-,%C7BG*,HVL>L6DZW-I%,IR'4&N&\;
M6'DWT=V@^648;ZUL>"K[[1IC6[GYX6X^AK0\26 O]'F0#+H-R_6O7K)8O!\R
MWM?YH\BBWA,9RO:]ODSRZBBBOECZD['P,Q^T3+VVYKMZXWP-$=EQ+CH=N:[*
MOK,K36&C<^3S-IXF5A&4,A4]",5Y3K=HUGJL\9&!N)7Z=J]7KE/&.E&> 7L2
MY9.' [BHS6@ZE'F6\2\JKJG6Y7M(R/!5XD&IO YQYH^7ZUW&H64>H64EM)PK
MC&?2O(T=XI Z,5=3D$=J[+2_&RK$L5_&=P&/,7O]:X<NQM*--T*NQW9C@JLJ
MBKT=RC/X(U"-R(9(Y$[$G!K4T/PB]E>)=W<@+(<JB],UK1^)])= WVM!GL<U
M#<^+M+@!VR^:?1*Z8X; 4Y>TYEIYG-+$X^I'V?+^!K7MPEK92S2-A54\UY%-
M*9YY)3U=BU:^M^([C5SY8'E0 _='?ZUBUYN98R.(FE#9'I9;@Y8>#<]V;?A6
M^-GK<:DX27Y#]:],(#J0>A%>,H[1NKH<,IR#7H-IXQTXVL8F8I(% 85UY5BX
M0@Z=1V[')FN$G.:J4U?N<?KUC]@UB>(#"$[E^E9H&3BNC\4ZEI^J&&:U?,J\
M,/:J.@:8VHZC&FW]V#EC[5YM:BGB'"EK=Z?,]*C6<<.IU=&EJ=SX7LS::.A8
M8>3YC6U3401QJBC 48%.KZVC35.FH+H?)5JCJ5'-]0ILB++&R.,JPP13J*T,
MSS?Q%H$FG7!EB4M QR".U<_7LD\$=Q$T4JAD88(-<1K7A&2%C-9 NG4KW%?.
M8[+90;J4E==NQ]'@<RC-*G5=GW[G)8HI\D,D3E)$*L.H(IE>.>P%%%%(844H
M!/2M73- O-1==L96//+G@5<*<JCY8*[(G4C37-)V10M+.6\N%BA0LQ/85Z;H
MFD1Z39A!S*W+M2Z1HEMI46$&Z4]7(YK3KZ7+\O\ 8>_/XOR/FLPS#V_N0^'\
MPHHHKU#RPHHHH **** *5YI-E?*1- I/J.#6%<^";60YAG=/;'%=517/5PE&
MKK.)T4L76I:0D<2W@:3=\LZX]ZEB\#)D&2Y('?:*[&BN=99AD[\IN\SQ+5N8
MQ;/PQIUH0WE^8X[M6PB+&NU%"CT Q3J*[*=&G35H*QR5*U2H[S=PHHHK0S"B
%BB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  R +,# 2(  A$! Q$!_\0
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I44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140130621447096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 05, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  05,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARDELYX, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-1303944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">400 FIFTH AVE.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">SUITE 210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">WALTHAM<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">745-1700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARDX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001437402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>ardx-20220505_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ardx-20220505.xsd" xlink:type="simple"/>
    <context id="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N180L2ZyYWc6ODMxMzU2MTRhOWM2NGUzZThiM2MzYjZiYmM1ZjI4ZGQvdGFibGU6YmY1ZWY1ZjAxNzE5NDRhY2IwOTRkNTM1NWU4NjA5YWUvdGFibGVyYW5nZTpiZjVlZjVmMDE3MTk0NGFjYjA5NGQ1MzU1ZTg2MDlhZV8yLTEtMS0xLTIyODA3_8c42eca7-2040-4148-a522-06df06dc2d29">0001437402</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N180L2ZyYWc6ODMxMzU2MTRhOWM2NGUzZThiM2MzYjZiYmM1ZjI4ZGQvdGFibGU6YmY1ZWY1ZjAxNzE5NDRhY2IwOTRkNTM1NWU4NjA5YWUvdGFibGVyYW5nZTpiZjVlZjVmMDE3MTk0NGFjYjA5NGQ1MzU1ZTg2MDlhZV8zLTEtMS0xLTIyODA3_ee43dacf-5a61-4c1e-9747-923da4f0e1aa">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGV4dHJlZ2lvbjo0MjkwOGMzYTVkMmM0NzE0YTE4NjA1M2RlZTIxMTY2MF8xMjYw_280c70ff-9661-45fc-875d-06a6547002e3">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGV4dHJlZ2lvbjo0MjkwOGMzYTVkMmM0NzE0YTE4NjA1M2RlZTIxMTY2MF8yMzE_951af91f-5fa7-4d92-a908-ea563436372e">2022-05-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGV4dHJlZ2lvbjo0MjkwOGMzYTVkMmM0NzE0YTE4NjA1M2RlZTIxMTY2MF8xMjYx_559f793c-c3ab-4422-82f7-1bed5a7c8158">ARDELYX, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGFibGU6YzVjOTI4ZDBmMWM4NGMwZWI0OTA2YzA2ZjYxYmQyMmIvdGFibGVyYW5nZTpjNWM5MjhkMGYxYzg0YzBlYjQ5MDZjMDZmNjFiZDIyYl8wLTAtMS0xLTIyODA3_cd7b2dbd-7697-4c32-8dbf-26e9bf3b5059">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGFibGU6YzVjOTI4ZDBmMWM4NGMwZWI0OTA2YzA2ZjYxYmQyMmIvdGFibGVyYW5nZTpjNWM5MjhkMGYxYzg0YzBlYjQ5MDZjMDZmNjFiZDIyYl8wLTEtMS0xLTIyODA3_87f7d3e0-6cbd-496a-a160-4e345e28d77c">001-36485</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGFibGU6YzVjOTI4ZDBmMWM4NGMwZWI0OTA2YzA2ZjYxYmQyMmIvdGFibGVyYW5nZTpjNWM5MjhkMGYxYzg0YzBlYjQ5MDZjMDZmNjFiZDIyYl8wLTItMS0xLTIyODA3_f929f8b6-447d-4ee0-bcd6-657084ec6304">26-1303944</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGV4dHJlZ2lvbjo0MjkwOGMzYTVkMmM0NzE0YTE4NjA1M2RlZTIxMTY2MF8xMjU0_b465c7d9-37fc-45be-bf0c-9523ba50a5b8">400 FIFTH AVE.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGV4dHJlZ2lvbjo0MjkwOGMzYTVkMmM0NzE0YTE4NjA1M2RlZTIxMTY2MF8xMjU1_3f97c815-d244-441e-b3a7-0dd8c334317a">SUITE 210</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGV4dHJlZ2lvbjo0MjkwOGMzYTVkMmM0NzE0YTE4NjA1M2RlZTIxMTY2MF8xMjYy_d8eb9ee7-255e-4375-9f2b-80e1ffffedd7">WALTHAM</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGV4dHJlZ2lvbjo0MjkwOGMzYTVkMmM0NzE0YTE4NjA1M2RlZTIxMTY2MF8xMjYz_07327b37-e616-40f2-ae48-4484672abe5e">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGV4dHJlZ2lvbjo0MjkwOGMzYTVkMmM0NzE0YTE4NjA1M2RlZTIxMTY2MF8xMjU2_a71ea345-d527-4d52-b848-179353814431">02451</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGV4dHJlZ2lvbjo0MjkwOGMzYTVkMmM0NzE0YTE4NjA1M2RlZTIxMTY2MF8xMjY1_de5bf237-d03b-4e6f-8b1d-8d29d6d475ff">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGV4dHJlZ2lvbjo0MjkwOGMzYTVkMmM0NzE0YTE4NjA1M2RlZTIxMTY2MF8xMjU3_bcf75b2b-2986-4df4-b256-400ecc79fe52">745-1700</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGFibGU6YzRmMzRkOWEzMjk3NDM4YmE2Mzk3ZGM4YjNlZDg4YjcvdGFibGVyYW5nZTpjNGYzNGQ5YTMyOTc0MzhiYTYzOTdkYzhiM2VkODhiN18wLTAtMS0xLTIyODA3_ed52a09d-d95e-432d-940b-41f693440027">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGFibGU6YzRmMzRkOWEzMjk3NDM4YmE2Mzk3ZGM4YjNlZDg4YjcvdGFibGVyYW5nZTpjNGYzNGQ5YTMyOTc0MzhiYTYzOTdkYzhiM2VkODhiN18xLTAtMS0xLTIyODA3_958580c8-68f0-4da9-b315-a03f300eb14f">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGFibGU6YzRmMzRkOWEzMjk3NDM4YmE2Mzk3ZGM4YjNlZDg4YjcvdGFibGVyYW5nZTpjNGYzNGQ5YTMyOTc0MzhiYTYzOTdkYzhiM2VkODhiN18yLTAtMS0xLTIyODA3_d6dfccba-46ce-4627-a18e-f62707441bb2">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGFibGU6YzRmMzRkOWEzMjk3NDM4YmE2Mzk3ZGM4YjNlZDg4YjcvdGFibGVyYW5nZTpjNGYzNGQ5YTMyOTc0MzhiYTYzOTdkYzhiM2VkODhiN18zLTAtMS0xLTIyODA3_aec8fadb-14e7-4526-8c29-508d1a407325">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGFibGU6ZDM0NTY1YTNkOTA3NGI0MWFiYTBjOGE3YWJmNWU2YWMvdGFibGVyYW5nZTpkMzQ1NjVhM2Q5MDc0YjQxYWJhMGM4YTdhYmY1ZTZhY18xLTAtMS0xLTIyODA3_a6e967f6-befb-4e43-ace9-51671bfdb04a">Common Stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGFibGU6ZDM0NTY1YTNkOTA3NGI0MWFiYTBjOGE3YWJmNWU2YWMvdGFibGVyYW5nZTpkMzQ1NjVhM2Q5MDc0YjQxYWJhMGM4YTdhYmY1ZTZhY18xLTItMS0xLTIyODA3_202fd247-181e-4b91-b729-5a83fa02fc2b">ARDX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGFibGU6ZDM0NTY1YTNkOTA3NGI0MWFiYTBjOGE3YWJmNWU2YWMvdGFibGVyYW5nZTpkMzQ1NjVhM2Q5MDc0YjQxYWJhMGM4YTdhYmY1ZTZhY18xLTQtMS0xLTIyODA3_1f0db5c8-5479-476e-8862-3faa68d1bb71">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1NGVhZGYzOTM4ZjRlYjZiMGY5ZGIzNmFkZGIwMDg3L3NlYzo4NTRlYWRmMzkzOGY0ZWI2YjBmOWRiMzZhZGRiMDA4N18xL2ZyYWc6NDI5MDhjM2E1ZDJjNDcxNGExODYwNTNkZWUyMTE2NjAvdGV4dHJlZ2lvbjo0MjkwOGMzYTVkMmM0NzE0YTE4NjA1M2RlZTIxMTY2MF8xMjU4_5e247c73-a828-44b3-b8d1-c45eb5c1a59b">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ :H"E5*K$(A8S 0  (@(
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M%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " !J@*5499!YDAD!  #/ P  $P
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M@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( &J
MI50'04UB@0   +$    0              "  0    !D;V-0<F]P<R]A<' N
M>&UL4$L! A0#%     @ :H"E5'("M:;M    *P(  !$              ( !
MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ :H"E5)E<G",0!@
MG"<  !,              ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " !J@*54QQ&M4SD$  "X$   &               @($,"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ :H"E5)^@&_"Q @
MX@P   T              ( !>PP  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" !J@*54EXJ[',     3 @  "P              @ %7#P  7W)E;',O+G)E
M;'-02P$"% ,4    " !J@*54JL0B%C,!   B @  #P              @ %
M$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ :H"E5"0>FZ*M    ^ $
M !H              ( !H!$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ :H"E5&60>9(9 0  SP,  !,              ( !A1(
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  SQ,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ardx-20220505.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="ardx-20220505.htm">ardx-20220505.htm</File>
    <File>ardx-20220331xexhibit991.htm</File>
    <File>ardx-20220505.xsd</File>
    <File>ardx-20220505_lab.xml</File>
    <File>ardx-20220505_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ardx-20220505_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ardx-20220505.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "ardx-20220505.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ardx-20220505_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ardx-20220505_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ardx-20220505.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ardx",
   "nsuri": "http://www.ardelyx.com/20220505",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220505.htm",
      "contextRef": "i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.ardelyx.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220505.htm",
      "contextRef": "i35600ca6d13c4ea0aa192d4f75c3e59d_D20220505-20220505",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001628280-22-012619-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-012619-xbrl.zip
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MCB>&[#,ZDHJKR"F^!9$)Q'.<J.$+I?>!9H'9?O?!0 7ZO&@!->5AH\WM[]T
MIRQHQ'3H?T<_ZZ26*@65NJD5S%*B<<@31WSB\6G$)_;TR-3QV[#@/4_EAC:0
M&7D ]P+D7E>?FO%,RR^5M&BJ R/C[+!6W-?O^4$<IE(498$$@@FUQ.T%/L#'
MOBM" 0DE0%2QO>.O)_LH3!P0'R VPN),AIX(/D_KM5GA:!TG+HU>P<VY<33]
MRDR#*?MG+QC)F*XHM$'M?"_P#DC%0^X^\&'X;GL"YSLINZ@=:9J/&Y+@[@)A
M8>B5?*AN()3[0MPD@:W^CB82R&1XUW5YVP^4W 6?.O(P8/=UZ#]P$,P@,< P
M*;+SR"D:I%EA'FVH2M#F,$,Z._B#0&@29 .862KF@*"@-#?K1?8''*N2 #2'
M>@.>HCDEX9%V D%*<  >K1,E/[3F'Y+E$:!X<<#/3Z)9\0 &>1@:))L$AM/6
MQG>  00"DWS$ =@(R>OCBX-(B@>T2R\K)O\HWA;9ATJ)P3&["DU#L@X1N <?
M;$<.)KL @^(NM?=@"&$<C$ $MP-H]A]0_&;@^A5L*/ YR975/F=Z+A<@D,$.
M(ROHBX"]]PQV#@<%'C=:0]^$VT'K<._BR_FW?;)9T5X<#-S4FP9$]E,+;"SJ
MD5K(J6$5"D"$,QMH7 5YPJP?A:.Y %%JA<R,./^4AYP>2W'L6&1($5A7_HEK
MX :N>RC7RR-]!"MU ]Z? #M_$=P,GC2&G5T_)#8 DS,. MP3A@!L98$@X(!X
MH8@MV0V= 6XTH3F-E!YW.XA@LDEPC9FS8LA"1BHNH4,<0,L.6,UA&M^@!0+1
MY8&3;#I[:C.7+BOB&N.#) !"W(+A["2 T@,Y N@"]L2MPADRQX^18!W@3QWE
MYDBZA:'@ 0;,I.^0[X!W,:-C'[DOF5 P,EJ&SS0)$5+[TBG@[?/X2L2_HL\E
M"0#MH20; <77GZVV=QIB40UA59\*-6@K_(I"PG@L"-9)$'=#MG=U>0+>\['R
MUO ,\7=V"FP2*SI5EYI@A@5V#^RPD].;_>1D25I^]GV'!M&++:>OQ)GVF<$9
MANF15T<W-4C[L)KLCP6(M9Q.98]F#!?ODW!!X!W!W61I<*'!VP#.N$FF.!<1
M;F'O^.9\?Q1V!!C^'H.2LAJ$)%"FF6"P8C3  $8G$TQEM$$FK$AK(B>#  GM
MV.6!1@R.TSO7X<OC-'PY$8)4H<EL)/+!CUT'^9K0K?5,$M1,%%;"GJ,@I0!W
MV.MV8I<">TD@(+7)@:756Z+3 9$%8JF/<8R :R4]B>E'17&*JC4(>3Z:1: O
MZ5]! /W$0.E;"#)UKSG]Y\\1</DG=\S#'KO6?A?=1R_3I68MXJJ<6V"Z@>IQ
M-"XCO$$#L WZDXG_QA*XF#Q9,AW(A^[3OV&N#XUFL:[FTJ:E@==@)*T#9:P^
M>TK3K$W,B5/"DQ.0?OVV",9@-]=8]ZXBR5[KR.XM>B/+)]EO:'G9?M>C>]GT
MNBYKSB6Q:/*?#'*E4,(G454G)J5!5*^$IS91>9\"STARI6)UC.#6F*:61SOY
M]MSQF'M^ V:/%XN5H*NN\(0R'CZ8#77\4<^/0R63)N(*@0(\=0>>3*R9DH,?
M:L7:N%2;=RY3&73@A@44-=1I ?D /I!-*L&M!:QISP4M!+(UV8=J<10$T#E-
MY###;P+CT3!!3P*C@#X T]A+PA]H8<+$#P+\-?A;LV02<M 7-O<2L$?Y$=I*
MC0=@9'JC4$)J<G[]>HPQE2;"IBQPE5>5W= HYD/V*^X+3$,,S"BX]#5\(AH(
M*H6"<6W!1EC<!5=WP=4-5]\WO[PO-XY.V"DX9> ^ALL4LBH!\R;+XEF1(S2(
M(%4" 99DL;F8>$11.Q*.RH*<$+48V&55,"L_&N,RV9K4_,\1RD_O3'JV&SN4
M)N05R/BEI#2" 48H0:='ZV! X/\ 7HO DX5]%*U46.,:\(.9_J"M& UGF 64
M93 #KRGQC4$)<)M!FKG#?(62T,X(_-FJA)SQD6L=1K&#&4XA1LP2*7]U?7=V
M<?;O4_74T.^,@J! 8#%>GBL#+5V5] QX(_<",_=BBLO9?$ 9W'\*O0@/0Q^L
MOS0(D<G#TTHIL?_@;?0PO,A/LO@4'.EZ>.*I'AH/'0I7@HA-0^N(I-'(V!L+
M\'=\#'"D=*."GH\IG9U\6T"^W?Z-B+25"KCEFY*W8!3!.1K:H'2)QG@F8 B$
M/"'KS&:QO+BP0Y++2#NK:$T+.],J-B>%G5DOF@L+NV?M\H5RSRI6Q^6>E;%:
M7R[W4NS!5.&S#F_,MG94LF[V.,AMR!-/8!UCMJ_*2ACE$>1DIVNQM9,;KRLW
M+D7$SOU0B8NE)K8@)"YFE\_-\D1W'ZS&!/<2GW\H%2T3[[]8V -&G^#X<CE/
M-L [Y4KVG?G%P&I'RZOH]$S6;YV(B$OW>=G!RZ&,; H:W8SV?,S[Q!N39$<V
M[HA*A*9KL Q,2QNK3[M#(D"_'."CN\RI:B&4=OH&*UMJA)E6^!;(2Y]2*J2-
MZ:(B$;X3$!ELX)+\PS0FMM>HU?99O5XO6-52D^TY?A_3KNQ]I+V]BFGM@YRN
M%ZH5L\SVZ,K,TQE9^TKZAM\1[K9@__&EBD#H0HOQ,B]<N<A:H%+;H&*B)!!!
M*,)42NZ&- NW;=@3S-,>LGN);KJV[LXH\ Q H:^=OJX.X%=4U6T8+!"K6-/,
M=9HK#" PD[MK?@_D19=<.BDT>0^Y"@X"SBJ<,"L)\A<0Y$_,#)RN<ZT"I9Y=
M7%_=W+4N[]AMZ_/IW;_8V>7GJYN+UMW9U>4S]Z6RE--P"B Y*% @:!"*P^0_
MCAP98F;LH?0(&'IIH9!#J50LJ=A(!.!$3K*R?ERD1P>1,_VL"195J3KS<:EH
MSGSVV+258J,YWZP'!+&"&A 3 IG^]5WYW9-$H9&JS(4!$)'O2H<AD22/*"@T
M_D0;&8?6X <SQ\-%.-%4ZCPA^>?7B=-1?FO=7)Y=_DV'&\YNO[*KS^SV].;L
MZH];=G+ZY5\G-T290*7L^O3DK'5W<W;,KN&WT\N[VY0F-?X70&V@@'DN;DN(
MV8G3G0BMF54:\7HGGKOV*^[ZL;V]Q3Y6BS[S]7JFG()2A_FHBD%ZHT1A5U#)
M(6BN&L.L)HIB@V8"NFX>X4APIL8"+E*E"PX!<UWVG_A>>)@2!EY&..;!Z!A]
M&G:Q.95C.()'O9 2V^.^LA?;(G%J'-$;.NIE4+'WOL2N'"(;5LE"GL"+J5KI
M)DQK;!?*]0IY1T1#54M)61P2"]_",#LS17X\/U(5DZ"A0=C+L#<36V9C?*&W
M8NB?Q;9:G^6+DS?FZ4?7?B96#DA+/[,>;W<3LT(W,:MC=:ILFJO+NYO6V>7)
MV3'I\]N?$R)YVZK.)5?YY%_:OU!C)5J$K@PDN'.J4@:OA\<UR^X EWN %)O\
M[OD/'OKF84R14BQ[4[6):&ATP;4.?'33P8?W5(%5%*AKEED^[,I(#.T9W++6
MY0F[OCD];OV1+SA6#.X;S32WFFE.1DR#YW<M',FC0-KL6I_DCI&6RTAM@34*
MM04MWKGLVMEV,343R?,"]C*3L0<A@*9<1[D3F1L7UHO[5&,E,JF9=,>;OCUN
MRN\;Z=6QP["['E-HU??@Y%;X-A68.,;3#H:1B8[Y= 4SVWDAG :"ZLH]F(5'
M/!. PWML%TLT)M"0NT'K,:=E?Z>;WHREE#N)ML&+7<J6BQE[7;K^GZ"*?%HP
M6!?YCU;7E)IXT#!4N<Y)=2#@#A<:N=QCG P_V<-TJ4$JD9,=&$"7K[7/55=7
M)Y('04_P6<44*T*.&4#Q1HT:./@ZE]BG1CTB" 75G::)'0\^4(7G^'U,,C1T
M%5H!!*^'H@UH1+3]@BX(QQZ!$?+SJ&$%WIO?(VDZV973]FV86UFL?LP01R'2
M35 3"BDN-;<A]Z9TZ<=XAN[$.%I)WP#3D0V+:LBG)K(J252I&I'@=.7YZ>+J
M]HX=7UU<7%VRULG_GM[<GK*;T]8QV:XKSV1W3_ 5B=Q9Y(XW@C:V?[,%]G5K
ME*I'UD<Z1NKT1_77JDT*<MX^Y=.HP']*"GMF[2.[#UGE8SH,A'$;>1C]%^P.
M(SRJ9]TKT\!?WM=*1^9'&-5Q>12[M+A^!C\KLT;^^:>Z&]VSQEY:>6(:Q4M6
MGG(2!9GI@(2&]\CDSF\LF/8Z^IUZ'=V.]3HZ?KS7T>J@9$8YCKI8#X6@['=V
MK?HBM5&XG7F C[ZVH57*%?[\N_\#4/6-!QXE-E&I]*CXD^(Q<O3F(O?0JY3N
MT6K[<32>&;!24,_H;J.[-U!5P^JTGRU.%='JWF,3?;^,70_5%YE5$P)NS(.E
M"G1/HKB[C4#JC0Z%NEHH0D ^W[7^?*4CP/H!U9,M*24$_G D=5O&W'-EW<_=
MZ^GXZTFVI9.A*ZJP6<#NVFO]KKU^%D7:NO4#A@P"4/=A3'EKH/733@;*N1S)
M ^H*I)]:;.!'(/8ET&B(T;F(=_UN+)*N!P:[.?EGR2R/LCUA/! M9NR-F5/"
M%?=D;&EZ3V:EU%'J6?.=N]BN!MD&)@>QU<=:6I!(-B"<3]\OJ)YGP%*_O*_4
MCW 6@>VZDR9HE//GJ=[*A3#",%W2J0'F AW%V[XK;<;!+_")H7AZFP3 VLB<
M0VRJA'TJ'&J;.\V1XTC+)A6D=89Z\%A_G[1)S&<_C#U$-9A-^/-Q#YP) OVK
M1['/.^I]3:WE23(<<X\[/$5VMCQH4HGGY&@H/2"#3/8Z-IH)L ^=%#/-UA4Q
MS.A;&)_]X($'#COW?>K"3<JLGWM9L:H6YPS_5EUL@C1)BU/#=&^D+;A.6X6'
M4F788,Q'6?(J1HG=2\;[F\)(/%LTQ; F*LRT6$J-6UAVJ%NJ$FX+KL9M9OU
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MDY>32?BJL5=D$LH]EFF$20(L&4Q8B,1,>-,L.)?9!3#[1+HI+?MP*BU8!(2
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M6\%XN7;?+Q;0"79;O9S\!E!+ P04    " !J@*54E*8IWX<)   *"@  %
M &%R9'@M,C R,C U,#5?9S$N:G!GG=5W5!-('@?PA"20(%D-36 I"H(A(+U&
M6 6D2XTD@"9+* I$$%!*L'" @(0N32-!Z4T2@:!T44HP-*D!7$6J2E&(]$4X
MW'?EG_OC[K[S9O[YS9LWGS?S9O;']C\"CEB969H!@#P  /"@ ?;? 4P 4%Y>
M/EX(E(^/#P:#\@L(PP4.'1(0%Q0Z+"PE(2,M)2$I>>R$RLECLLIRDI)(745E
M-74M+2V9D_J&>AH&*II:&C\7 <)@,(%# F)PN)C&<<GC&O]S]EL!""B !""!
M@+( '@00A #NMP-D#O8) ?X5P#\"Y &!(;Q\4!C_H8,)M4< /$ 0B <,@D#
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MZ:L5 Z%(F!B+6](-VP>D^$2@K,F$P:_Z9DX% 1:[)$[_SN,M.%FAI*\L>!^
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M%0U/<14+J0W*DC<].(N8_E*QL6?UU,4''34KG31O$_(=C^3EB] $B653?D-
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MIGM'$3E@[M>*GA%SP-OS3SP7;%5L>T[8[K21MU^L_YTEJ8)S&<F(PQ !C*$
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M\&7(BM7A_/>+-T3/?SS:VWOU'2%__/3N;/9SZ:\V4#2SDPIL V%VG37KV8<
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M_U!E30/%2;G97!5WF^=ZJ;U(G6:.>,D5D59P8B)J(E*O!=5*::D&,?!%L_U
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M2P$"% ,4    " !J@*54\R@; VH"  !K!P  $0              @ 'U,P
M87)D>"TR,#(R,#4P-2YX<V102P$"% ,4    " !J@*54E*8IWX<)   *"@
M%               @ &.-@  87)D>"TR,#(R,#4P-5]G,2YJ<&=02P$"% ,4
M    " !J@*54+)V7D90*   180  %0              @ %'0   87)D>"TR
M,#(R,#4P-5]L86(N>&UL4$L! A0#%     @ :H"E5,TYB$73!@  ]#(  !4
M             ( !#DL  &%R9'@M,C R,C U,#5?<')E+GAM;%!+!08
..!@ & ) !   44@     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
